Jornayvaz François R
Unité de diabétologie, Service d'endocrinologie, diabétologie, hypertension et nutrition, HUG, 1211 Genève 14.
Rev Med Suisse. 2019 Jan 9;15(N° 632-633):38-41.
Diabetes is a rapidly evolving discipline, numerous new molecules and technologies are available. This allows for a better follow up of our patients with type 1 and type 2 diabetes. Moreover, every new molecule devoted to treat type 2 diabetes must undergo a cardiovascular safety study. In recent years, some of these studies proved to be beneficial for some of our patients. Nevertheless, this pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in trouble finding the right medication. This article will highlight novelties in the field of diabetes during the year 2018.
糖尿病是一个快速发展的学科，有众多新的分子和技术可供使用。这使得我们能够更好地跟踪1型和2型糖尿病患者。此外，每一种用于治疗2型糖尿病的新分子都必须进行心血管安全性研究。近年来，其中一些研究被证明对我们的一些患者有益。然而，矛盾的是，这种药理学上的过多药物与临床惰性相关，因为全科医生可能难以找到合适的药物。本文将重点介绍2018年糖尿病领域的新进展。
